Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
- PMID: 28444221
- DOI: 10.1093/ndt/gfx079
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
Comment in
-
Doubts about the efficacy of tolvaptan for polycystic kidney disease.Clin Nephrol. 2020 Jun;93(6):307-309. doi: 10.5414/CN109927Letter. Clin Nephrol. 2020. PMID: 32000887 No abstract available.
-
Reply to Dr. Anderson's letter.Clin Nephrol. 2020 Jun;93(6):310-311. doi: 10.5414/CN109927Reply. Clin Nephrol. 2020. PMID: 32000888 No abstract available.
LinkOut - more resources
Other Literature Sources